CLIMATE CHANGE: Health Scenarios for a Warming World by Cooney, Catherine M.
People get ready.
Curtis Mayfield (1942–1999)
A 382  v o l u m e  118 | n u m b e r 9 | September 2010  •  Environmental Health Perspectives
Climate Change
health Scenarios for 
a Warming World
A large fraction of emissions of carbon dioxide 
(CO2)—the  greenhouse  gas  produced  by 
human activities in the greatest quantities—is 
long lived in the atmosphere, so decisions made 
today to continue adding CO2 into the atmo-
sphere may lock future generations into a range 
of human health and environmental impacts, 
some  of  which  could  become  very  severe, 
according  to  a  committee  of  the  National 
Research  Council  (NRC).  In  a  report  that 
looks at the short- and long-term effects of the 
stabilization of Earth’s temperature, the NRC 
committee quantifies, as much as possible, the 
outcomes  of  different  stabilization  targets  for 
the planet, with a focus on the United States.1 
The  report  synthesizes  global  warming 
science in myriad fields along with research on 
the potential impacts for human health and 
other arenas. Then the committee adds a twist: 
rather than expressing climate goals in terms 
of  stabilizing  atmospheric  concentrations  of 
CO2, the authors assess such goals using global 
mean  temperature  change  as  the  primary 
metric. The twist allows the authors to link the 
potential impacts from climate change more 
directly to temperature change.
Research to date suggests many potential 
impacts can be directly linked to temperature, 
or to things that can be themselves linked to 
temperature (e.g., precipitation), although some 
(e.g., ocean acidification) are linked directly to 
CO2 concentration, says Damon Matthews of 
Concordia University, a report coauthor. “But 
in this report we were . . . noting the additional 
impacts you would expect for a given degree 
in global temperature change,” says Katharine 
Hayhoe  of  Texas  Tech  University,  another 
coauthor.  Given  the  anticipated  impacts  for 
anywhere from a 1- to 5-°C global temperature 
increase,  the  panel  “worked  backwards  and 
said, ‘If we picked a temperature target based 
on a risk that is acceptable [to society], then 
what does that imply regarding the CO2 levels 
we must aim for?’” according to Hayhoe. 
Things shifted for climate change research-
ers about five years ago, when climate models 
began to factor in the carbon cycle, making 
it  easier  to  include  specific  CO2  emissions 
scenarios and link them to temperature, says 
Matthews. In 2009 Matthews and colleagues 
described the framework for linking the tem-
perature response to carbon emissions, a con-
struct known as the carbon climate response.2 
The  carbon  climate  response—the  ratio  of 
temperature  change  to  cumulative  carbon 
emissions—“allows CO2-induced global mean 
temperature change to be inferred directly from 
cumulative carbon emissions,” Matthews et al. 
wrote.2 Three other papers published the same 
year3–5 proposed a similar framework and dem-
onstrated “a remarkably consistent temperature 
response to a given level of cumulative carbon 
emissions,” the NRC report notes.1
The  NRC  report  discusses  three  main 
types  of  health-related  stress  expected  from 
rising average temperatures: illness and infec-
tious  diseases  carried  by  animal  hosts  and 
mosquitoes  and  other  vectors,  heat-related 
illness and deaths, and health problems due 
to air pollution (e.g., related to increased ozone 
formation)  and  water  contamination  (e.g., 
related to more frequent heavy downpours).
In one discussion, the report summarizes 
research on a 1995 Chicago heat wave that 
resulted  in  692  heat-related  deaths  within 
the  city6 a n d  e x t r a p o l a t e s  t o  p r e d i c t  h o w  
many  heat  waves  and  deaths  might  occur 
with  each  degree  of  temperature  rise.  For 
instance, under a 2°C change in global mean 
temperature,  annual  average  mortality  rates 
are projected to equal those of 1995, whereas 
under a 4°C change in global mean tempera-
ture, annual average mortality is projected to 
be twice 1995 levels, and 1995-like heat waves 
are predicted to occur as frequently as three 
times per year.7
Yet  quantifying  the  impact  on  human 
health per degree of global temperature change 
is difficult, and must take into account many 
confounding  factors  including  behavior, 
says Christopher Portier, now director of the 
National  Center  for  Environmental  Health 
and  the  Agency  for  Toxic  Substances  and 
Disease  Registry.  In  his  former  position  as 
senior  advisor  at  the  National  Institute  of 
Environmental Health Sciences, Portier led a 
federal working group that released a report 
on 11 categories of disease and other health 
consequences that may occur due to climate 
change.8 That report highlighted a huge need 
for  research  to  better  understand  the  link 
between global warming and human health 
effects, Portier says. 
The NRC report was released a few days 
before  Senate  majority  leader  Harry  Reid 
(D–NV) announced there were not enough 
votes in support of climate change legislation, 
meaning Congress won’t pass a climate change 
bill  in  2010.  Tim  Profeta,  director  of  the 
Nicholas  Institute  for  Environmental  Policy 
Solutions at Duke University, says he read the 
NRC report the same day that climate legisla-
tion was failing in the Senate. “That created 
quite  a  juxtaposition,”  he  says,  “showing  us 
both the challenges we have before us and the 
amount of work that we have to get done.”
Catherine M. Cooney, a science writer in Washington, DC, 
has  written  for  Environmental  Science  &  Technology  and 
Greenwire.
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1–2°C of Warming
 FIRE
•  200–400% increase in area burned per degrees in 
parts of western United States
1–4°C of Warming
 RAIN
•	 5–10% less rainfall per degree in Mediterranean, 
SW North America, southern Africa dry seasons
•	 5–10% more rainfall per degree in Alaska and 
other high-latitude Northern Hemisphere areas
•	 3–10% more heavy rain per degree in most land areas
 RIVERS
•  5–10% less streamflow per degree in some river 
basins, including the Arkansas and Rio Grande
 FOOD
•  5–15% reduced yield of U.S. corn, African corn, 
and Indian wheat per degree
 SEA ICE
•  15% reduction in annual average Arctic sea ice 
area per degree
3°C of Warming
 COASTS
•  Loss of about 250,000 km2 of wet- and drylands
•  Millions more people at risk of coastal flooding
 TEMPERATURE EXTREMES
•  9 of 10 summer seasons are expected to be 
warmer than all but 1 summer of 20 in the last 
decades of the 20th century over nearly  
all land areas
4°C of Warming
 TEMPERATURE EXTREMES
•  About 9 out of 10 summers warmer than the 
warmest ever experienced during the last 
decades of the 20th century over nearly  
all land areas
5°C of Warming
 FOOD
•  Yield losses in most regions and potential 
doubling of global grain prices
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Selected Potential impacts1
(per degree global temperature increase)Forum
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Pharmaceutical 
Factories as a Source 
of drugs in Water 
Low levels of active pharmaceutical ingredients 
(APIs)  turning  up  in  natural  waterways  and 
drinking  water  supplies  are  coming  under 
increasing  scrutiny  for  their  potential  health 
effects  on  people  and  wildlife.  Human  waste 
has been identified as the main source of these 
pharmaceuticals, along with the common prac-
tice of flushing unused medications down the 
toilet. Now, a new study by the U.S. Geological 
Survey (USGS) highlights a largely overlooked 
contributor:  pharmaceutical  manufacturers.1 
Effluent  from  two  U.S.  wastewater  treatment 
plants that received discharge from pharmaceuti-
cal manufacturing facilities had levels of seven 
APIs that were 10–1,000 times higher than efflu-
ent from plants that received no such waste.
Between 2004 and 2009, USGS researchers 
sampled effluent and receiving water down-
stream from three wastewater treatment plants 
in New York State. Two of the plants received 
about 20% of their waste from pharmaceutical 
manufacturing  facilities;  the  other  received 
none.  Researchers  also  collected  effluent 
samples  from  23  treatment  plants  around 
the nation that did not serve pharmaceutical 
manufacturers.
The researchers analyzed the samples for 
seven APIs (see box). In effluent from the two 
treatment plants serving pharmaceutical man-
ufacturers, median concentrations of the most 
common APIs ranged from 2 to 400 µg/L. 
The researchers also found surprisingly high 
maximum concentrations of 1,700 µg/L for 
oxycodone and 3,800 µg/L for metaxalone. 
Moreover,  low  levels  of  two  of  the  APIs 
turned up in a drinking water reservoir 30 km 
downstream  from  one  plant.  By  contrast, 
in  effluent  from  treatment  plants  with  no 
pharmaceutical  manufacturers  among  their 
clientele,  concentrations  of  individual  APIs 
rarely exceeded 1 µg/L, a figure that aligns 
with previous findings from treatment plant 
effluent in the United States and Europe.
2,3
According to the authors, the USGS study 
is the first to directly link high concentrations 
of APIs in water to pharmaceutical manufac-
turers in the United States. This study follows 
a 2007 report of unprecedentedly high levels of 
API residues in effluent from an Indian treat-
ment  plant  serving  some  90  pharmaceutical 
manufacturers.
4  The  antibiotic  ciprofloxacin 
occurred at levels up to 31,000 µg/L—more 
concentrated than the maximum therapeutic 
levels in human plasma.
Scientists  have  assumed  those  findings 
wouldn’t  translate  to  the  Western  world, 
in  part  because  the  high  market  value  of 
pharmaceutical  products  presumably  moti-
vates  manufacturers  to  recover  as  much  as 
possible and keep discharges to a minimum. 
“The conventional wisdom when the India 
paper came out was, ‘Well, that just couldn’t 
happen here.’ . . . And in fact, it did happen,” 
says Patrick J. Phillips, the present study’s lead 
author. He adds that it remains to be seen 
whether the API levels his team found apply 
to effluents from other U.S. pharmaceutical 
manufacturers.
The human health effects of waterborne 
APIs are largely unknown. Phillips points out 
that high concentrations of some APIs would 
raise  greater  concern  than  others,  such  as 
antibiotics that may promote drug resistance 
in bacteria. Of the seven drugs his team mea-
sured, five are federally controlled substances,
5 
and  a  quick  calculation  suggests  that  for 
oxycodone, for instance, a person would need 
to drink just 1.4 L of effluent containing the 
maximum  concentration  detected  to  ingest 
the lowest commercial dose of the drug.
6
But  of  course,  people  usually  do  not 
drink  effluent,  and  while  praising  the 
study,  Christian  Daughton,  chief  of  the 
Environmental Chem  istry Branch at the U.S. 
Environmental  Pro  tec  tion  Agency  (EPA), 
points out that what really matters for human 
health  are  API  levels  in  finished  drinking 
water. So far these have typically been found 
only  at  minute  nanogram-per-liter  concen-
trations.  “There’s  very  little  evidence  that 
just about any chemical at that level has an 
effect on humans,” Daughton says. Of greater 
concern is the potential effect on aquatic life, 
since even low levels of anti  depressants and 
endocrine  disruptors  commonly  found  in 
sewage can profoundly affect fish and other 
organisms.
7,8
The USGS findings also raise the question 
of  transparency.  U.S.  manufacturers  have 
no  obligation  to  disclose  what  APIs  they 
produce or discharge, so Phillips’s team relied 
on  a  time-consuming  “forensic”  approach: 
they chose the seven com-
pounds  for  analysis  only 
after  noticing  unusual 
chro  matograph  spikes  in 
water  samples,  and  then 
painstakingly  developed 
detection  methods  for 
each one. Phillips says that 
since he’s shown that APIs 
from  factories  can  get 
through  treatment  plants 
and into reservoirs, manu-
facturers  should  share 
more  information  with 
environmental monitors.
In  response  to  the 
study,  the  Pharmaceu  ti  cal  Research  and 
Manu  fac  turers of America asserts that factories 
comply  with  environmental  regulations  and 
that APIs detected in surface waters “come pri-
marily from patient use.” The pharmaceutical 
company Pfizer comments, “Previous studies 
have indicated . . . that the contribution from 
manufacturing  operations  is  negligible.  We 
look forward to subsequent work in this area to 
further understand the issue.”
Attention to the patient side of the equa-
tion has been gaining momentum. Take-back 
programs are cropping up across the nation 
as a way for consumers to safely dispose of 
unused medications.
9 And the U.S. Senate’s 
Special Committee on Aging held a hearing 
on the subject in June. Committee chair Herb 
Kohl (D–WI) called for more take-back and 
waste-reduction programs to be implemented 
and for harmonization of contradictory fed-
eral  guidelines  on  proper  pharmaceutical 
disposal. Opening the hearing, he echoed the 
sentiments of many scientists when he stated, 
“While we don’t know yet what impact this 
has  on  humans,  we  can  all  agree  that  it’s 
disturbing  to  think  about  leftover  drugs 
tainting our drinking water.”
10
Rebecca  Kessler,  based  in  Providence,  RI,  writes  about 
science and the environment for various publications. She is 
a member of the National Association of Science Writers and 
the Society of Environmental Journalists.
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  Drug  Usage
  methadone  opioid pain reliever
  oxycodone  opioid pain reliever
  butalbital  barbiturate
  carisoprodol  muscle relaxant 
  metaxalone  muscle relaxant 
  diazepam  tranquilizer 
  phendimetrazine  amphetamine 
drugs measured are  
federally controlledForum
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Asian Tiger Mosquitoes  
Roar Indoors
A new study from Penang Island, Malaysia, 
finds  that  the  Asian  tiger  mosquito 
(Aedes albopictus) is adapting to indoor 
environments, a factor that could increase 
vector–host contacts and the population 
density of the vector, thereby potentially 
increasing  the  diseases  spread  by  this 
vector.1 The study showed the indoor-
adapted mosquitoes had a longer lifespan 
and completed more reproductive cycles 
than outdoor-breeding mosquitoes. Asian 
tiger mosquitoes spread dengue viruses, 
chikungunya, yellow fever, and encephalitis 
viruses. These mosquitoes are linked to a rare 
U.S. outbreak of dengue fever in May 2009.
New Cigarette Label Regulations 
Take Effect
Although consumers may assume cigarettes 
labeled light, low, or mild are healthier than 
regular cigarettes, there is no substantial 
scientific evidence that proves low-tar 
cigarettes  cause  fewer  smoking-related 
health effects. Since 22 July 2010 those 
labeling terms have become off limits to 
cigarettes distributed in the United States 
under the Family Smoking Prevention and 
Tobacco Control Act of 2009.2 By July 2011 
the U.S. FDA will establish requirements for 
large cigarette health warnings on labels, 
including  color  graphics  depicting  the 
adverse health effects of smoking, says FDA 
representative Kathleen Quinn. 
Light-Colored Roofs Cool Cities
Roofs and pavements cover 50–65% of 
urban areas. Using a detailed NASA global 
land surface model, researchers have found 
that light-colored rooftops and road surfaces 
can offset the heating effect of up to two 
years of current global CO2 emissions.3 
The Beat | by Erin E. Dooley
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genetically engineered 
Salmon on the Fda’s table
This fall the U.S. Food and Drug Administration (FDA) is expected 
to decide on the first-ever genetically engineered (GE) nonplant food 
source for human consumption—a proposal by Massachusetts-based 
AquaBounty to sell sterile eggs of a salmon with genetic material from 
the Chinook salmon and the ocean pout inserted for fast growth. 
Growers who buy the eggs can raise market-size salmon in 16–18 
months instead of three years.
1 But consumer groups have questioned 
what they call a secretive FDA process for evaluating foods developed 
from GE animals. 
The rubric for regulating genetically modified animals differs 
from that used for crops, notes Greg Jaffe, biotechnology project 
director  at  the  Center  for  Science  in  the  Public  Interest,  a  non-
profit consumer advocacy group in Washington, DC. “They use the 
animal-drug rubric because that’s the legal construct they have,” Jaffe 
says. “But it’s like jamming a square peg in a round hole” because 
there’s more secrecy in developing drugs than for foods. Still, he says, 
“it’s better than what we have on the crop side.”
Using the same legal basis as for animal drugs—and unlike the 
process for crops—the FDA’s process for animals is mandatory and 
requires approval before going to market. But although the FDA 
may provide a public-comment opportunity in conjunction with the 
Advisory Panel meeting it calls for each modified animal it reviews, 
Jaffe says the agency can issue its findings without providing all the 
underlying data, which requires consent from the company. “The 
FDA doesn’t control completely the transparency of its regulatory 
process,” Jaffe says; for that reason, he says, “I don’t think it goes 
far enough.”
The FDA process is outlined in a document called Guidance 
for Industry (GFI) 187,
2 released in January 2009. According to 
Larisa Rudenko, senior adviser for biotechnology at the FDA Center 
for Veterinary Medicine, GFI 187 clarifies the agency’s statutory 
authority for regulating GE animals and lays out recommendations 
for how producers of those animals could submit data to the agency 
for review.
As described in GFI 187,
2 the FDA requires a proposed GE change 
be stable for at least two noncontiguous generations sampled across a 
minimum span of three generations. The agency examines the health 
of the animal and the safety of any products from those animals that 
are consumed by humans, and assesses risk to the environment given 
the description of how the animal will be raised. The FDA uses a 
risk-based assessment of potential hazards and likelihood of harm.
Assessments  are  made  on  a  case-by-case  basis,  emphasizes 
Rudenko.  “We  wanted  to  write  a  guidance  at  a  sufficiently  high 
altitude” that it would apply to all GE animals. She adds that “the 
FDA neither supports nor opposes [biotechnology]. We’re making a 
science-based decision.”
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The increased reflectivity of these surfaces 
allows entire buildings and surrounding 
areas to maintain cooler temperatures. 
The result: less energy is required to keep 
indoor temperatures comfortable. The study 
looked at the effect of changing urban 
surfaces to cooler colors, not just bright 
white—a color that may not appeal to some 
homeowners. In July 2010, DOE Secretary 
Steven Chu announced a federal initiative 
under President Obama’s Executive Order 
on Sustainability to implement cool roof 
technologies on government facilities.4
Stronger Ozone Layer Protection 
May Reduce Cataract Incidence  
A new EPA report indicates stricter 1997 
amendments to the Montreal Protocol may 
be paying off.5 The report predicts more 
than 22 million additional cataract cases 
may be avoided in Americans born between 
1985  and  2100  thanks  to  successful 
ongoing efforts to repair the Earth’s ozone 
layer. The EPA report used the recently 
updated Atmospheric and Health Effects 
Framework  model  to  predict  avoided 
cataract cases. According to the U.S. EPA, 
the ozone layer is expected to recover to 
pre-1980 levels by 2065.
Hotter Nights May Affect Asian 
Rice Crops
A  six-year  study,  the  first  of  its  kind 
using real-world data, shows that hotter 
nights affect rice productivity, and that 
with continued climate change the effect 
may worsen as this century progresses.6 
The  authors  found  increased  nighttime 
temperatures  affected  a  key  stage  in 
ripening known as grain filling—perhaps 
because energy the rice usually  spent 
ripening  was  diverted  to  increased 
respiration. They predict the scenario may 
get worse as daytime temperatures increase 
to certain predicted levels, which also may 
restrict the growth cycle of rice plants.
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The divide over foods derived from GE animals has remained 
consistent  for  years,  notes  Marion  Nestle,  a  professor  in  the 
Department  of  Nutrition,  Food  Studies,  and  Public  Health  at 
New York University. Compared with agricultural crops, she says, 
issues surrounding GE animals are mainly environmental, includ-
ing  concern  that  the  animals  could  escape  and  breed  with  wild 
populations. 
In the case of the AquaBounty AquAdvantage® salmon, only 
sterile female eggs  will  be sold  to  growers,  and the  fish  will be 
grown in contained inland systems, according to the company’s 
application to the FDA. The main environmental concerns with 
the  AquAdvantage  salmon  involve  the  possible  impact  on  wild 
salmon,  specifically  the  possibility  that  some  eggs  might  not  be 
sterile and end up being fertilized, and that the transgenic salmon 
might thus get established in marine ecosystems, where they could 
influence wild relatives, says Calestous Juma, director of the Science, 
Technology and Globalization Project at Harvard University. 
“Though  the  chance  of  such  events  occurring 
remains  minimal,  it  will  be  essential  to  monitor 
the technology’s use,” Juma says. Indeed, he adds, 
monitoring  will  address  the  main  challenge  of 
GE  animals:  how  to  generate  trust  in  the  new 
technology.
Given  the  depletion  of  fisheries  stocks  world-
wide, says Juma, the AquAdvantage salmon could 
represent  a  significant  way  to  increase  protein 
production while reducing pressure on natural fish 
stocks. He calls it “one of the few examples where 
a new technology demonstrates clear human–envi-
ronmental  benefits,”  with  potential  for  improving 
food security globally. He adds that this technology 
could help developing nations bypass a growth stage 
of  aquaculture  involving  heavy  use  of  antibiotics 
and other chemicals, and instead leapfrog to more 
ecologically sound aquaculture.
“The public will see this has been a very thorough, careful 
evaluation,”  says  Rudenko.  “We’re  committed  to  making  this 
[process] as transparent as we can.” She adds, “This is a mandatory 
approval process—what’s flexible is how one presents the data.” 
As for what’s next for the AquAdvantage salmon, a representa-
tive for the company who requested to remain anonymous says 
AquaBounty received notification this summer that the agency 
had the bulk of the information needed for a decision.
David A. Taylor writes for The Washington Post and Smithsonian and is author of Ginseng, 
the Divine Root, about the science and subculture surrounding the medicinal plant. He teaches 
science writing at The Writer’s Center in Maryland.
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Sterile AquAdvantage
® 
eggs (opposite) will be sold 
to growers and yield only 
female fish (shown in rear, 
below, compared with a 
nontransgenic Atlantic 
salmon of the same age).
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